Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma-Reference-Cited by-全球学者库

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma

Published:2016-12 Issue:12 Volume:11 Page:2129-2140
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Li Shiyong,Choi Yoon-La,Gong Zhuolin,Liu Xiao,Lira Maruja,Kan Zhengyan,Oh Ensel,Wang Jian,Ting Jason C.,Ye Xiangsheng,Reinhart Christoph,Liu Xiaoqiao,Pei Yunfei,Zhou Wei,Chen Ronghua,Fu Shijun,Jin Gang,Jiang Awei,Fernandez Julio,Hardwick James,Kang Min Woong,I Hoseok,Zheng Hancheng,Kim Jhingook,Mao Mao

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference49 articles.

1. Comparison of aspects of smoking among four histologic types of lung cancer;Kenfield;Tob Control,2008

2. Worldwide trends in lung cancer pathology;Gabrielson;Respirology,2006

3. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women;Cheng;Cancer Res,2001

4. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers;Le Calvez;Cancer Res,2005

5. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications;Kosaka;Cancer Res,2004

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway;JCI Insight;2023-11-08

2. Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages;Lung Cancer;2023-10

3. Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug;Frontiers in Chemistry;2023-09-07

4. New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment;Journal of Translational Medicine;2023-08-31

5. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial;The Lancet Respiratory Medicine;2023-07